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Background: Adverse drug events are a frequent cause of emergency department presentations. Administrative
data could be used to identify patients presenting with adverse drug events for post-market surveillance, and to
conduct research in patient safety and in drug safety and effectiveness. However, such data sources have not been
evaluated for their completeness with regard to adverse drug event reporting. Our objective was to determine
the proportion of adverse drug events to outpatient medications diagnosed at the point-of-care in emergency
departments that were documented in administrative data.
Methods: We linked the records of patients enrolled in a prospective observational cohort study on adverse drug
events conducted in two Canadian tertiary care emergency departments to their administrative data. We compared
the number of adverse drug events diagnosed and recorded at the point-of-care in the prospective study with the
number of adverse drug events recorded in the administrative data.
Results: Among 1574 emergency department visits, 221 were identified as adverse drug event-related in the
prospective database. We found 15 adverse drug events documented in administrative records with ICD-10 codes
clearly indicating an adverse drug event, indicating a sensitivity of 6.8% (95% CI 4.0–11.2%) of this code set. When
the ICD-10 code categories were broadened to include codes indicating a very likely, likely or possible adverse
event to a medication, 62 of 221 events were identifiable in administrative data, corresponding to a sensitivity of
28.1% (95% CI 22.3-34.6%).
Conclusions: Adverse drug events to outpatient medications were underreported in emergency department
administrative data compared to the number of adverse drug events diagnosed and recorded at the point-of-care.
Keywords: Adverse drug event, Adverse drug reaction, Administrative data, Emergency department, Validation,
Post-market surveillance, Drug safetyBackground
Outpatient medication use is common, but may confer
health risks that compromise its therapeutic benefits [1-3].
Health risks associated with medications have been shown
to vary substantially in clinical practice from those observed
in published randomized controlled trials [4,5]. Capturing
complete data on adverse drug events observed in clinical
practice is important for post-market surveillance, drug* Correspondence: chohl@mail.ubc.ca
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reproduction in any medium, provided the orregulatory activities, and research in drug safety and effect-
iveness and patient safety [6-8].
Emergency Departments play a pivotal role in North
American healthcare systems [9]. They serve as acute
diagnostic and treatment centers for ambulatory patients
with unexpected and serious medical problems, as a safety
net for the underserved and uninsured, and are an access-
ible portal of entry into acute care hospitals for sick pa-
tients. A growing proportion of urgent outpatient visits
occur in emergency departments, and the majority of hos-
pital admissions in the United States occur through emer-
gency departments [9]. Ambulatory patients suffering
from serious adverse drug events, the unexpected andd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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seek care in emergency departments [10-15]. Therefore,
emergency department administrative data may offer
unique opportunities to track population-level data on
clinically significant adverse drug events to outpatient
medications for the purposes of surveillance and research
[16-20].
Administrative databases are readily available, inex-
pensive and can provide population-level health data on
important health outcomes [8]. However, emergency de-
partment administrative data have not been evaluated
for their completeness in adverse drug event reporting.
Our objective was to determine the proportion of ad-
verse drug events identified at the point-of care in two
emergency departments by pharmacists and physicians
that were recorded in administrative data.
Methods
Study design
We linked data from a prospective observational cohort
study to emergency department administrative data [21].
We obtained data on patient demographics, emergency
department visits, and adverse drug events to outpatient
medications from the prospective study. We used each
patient’s unique identifier and emergency department
visit date to link the prospective study database with ad-
ministrative databases to look for records of adverse
drug events within the administrative data. The adminis-
trative databases used ICD-10 diagnostic codes, and one
also recorded chief complaint codes. The University of
British Columbia Clinical Research Ethics Board (H10-
01632) reviewed and approved the study protocol, and
waived the need for informed consent.
Setting
We used data collected as part of a prospective observa-
tional study that was conducted in two tertiary care
emergency departments in Canada with a combined
census of 145,000 patient-visits per year: Vancouver
General Hospital (VGH) and St. Paul's Hospital (SPH).
Study cohort
Our study cohort consisted of patients enrolled into the
prospective study. Patients were eligible for enrolment if
they presented to the VGH or SPH emergency depart-
ments between July 1, 2008 and January 24, 2009.
Research assistants enrolled patients using a previously
described systematic patient selection algorithm to gen-
erate a representative sample. We included all English-
speaking patients who were 19 years of age or older and
reported using at least one prescription or over-the-
counter medication within two weeks of presentation. In
the prospective study, we excluded patients if they were
agitated, presented with intentional self-poisoning, hadpreviously been enrolled, presented for a scheduled re-
visit, had been transferred from another hospital, or left
against medical advice or prior to being seen by the
physician or pharmacist. When we linked the study data-
bases we subsequently excluded the records of patients
with multiple visits on the same day because they re-
sulted in unresolved linkages.
Identification of adverse drug events at the point-of-care
One of three residency-trained clinical pharmacists who
were research assistants in the prospective study and the
treating emergency physician assessed each patient for
adverse drug events in the emergency department in a
manner that was independent and blinded to each other’s
assessments using a pre-defined algorithm (Additional file
1): First, the pharmacists evaluated whether or not the pa-
tient’s visit was due to an adverse drug event using
three adapted causality algorithms [22-24]. The causal-
ity algorithms were used to standardize the pharma-
cists’ assessments, and to ensure that the exacerbation
of underlying disease was considered as a cause for any
events deemed potentially due to an adverse drug
event. Inter-rater reliability of the pharmacists’ assess-
ment using the causality algorithms was 0.75. After the
pharmacy assessment was complete, we interviewed
the treating emergency physician using a standardized
questionnaire to determine the patient’s working diagno-
sis. When the physician and pharmacist determinations of
a patient’s adverse drug event status were concordant (i.e.,
ADE/ADE or No ADE/No ADE), this was considered the
criterion standard. If there was any disagreement between
ratings (e.g., ADE/No ADE) or uncertainty (e.g., ADE/Un-
certain), an independent committee consisting of a clinical
pharmacist and a medical toxicologist (who was also a
physician), both of whom were otherwise not involved in
the study, adjudicated the cases (See Algorithm for adjudi-
cation committee, Additional file 1). If the case definition
of adverse drug events was met, we categorized the events
according to the Hepler & Strand taxonomy (Additional
file 2) [25].
Identification of adverse drug events in the
administrative data
We used administrative data that the Vancouver Coastal
Health Authority routinely submits to the Canadian In-
stitute for Health Information (CIHI) National Ambula-
tory Care Reporting System (NACRS). This database
contains data on emergency department visits and in-
cludes the patient’s diagnosis at the time of discharge in
addition to secondary diagnosis fields. We identified
adverse drug events in the administrative data using a
list of 650 ICD-10 codes generated through a review of
the literature [26] and from Stausberg et al., [27,28]
and by searching for relevant chief complaint codes
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codes that may indicate a manifestation of an adverse
drug event (e.g., K25 Gastric ulcer) or an external cause
(e.g., Y40-Y59 Drugs, medicaments and biological sub-
stances causing adverse effects in therapeutic use). To
search for categories of adverse drug events not classified
as adverse drug reactions, we also included Y66 (non-ad-
ministration of surgical and medical care), T36-50 (poi-
soning by drugs, including overdose and wrong substance
given or taken in error), T88.7-T88.9 (unspecified adverse
events of a drug, and unspecified complications of medical
care), Y57.9 (complications of medical and surgical care:
drug or medicament, unspecified), Y69 (unspecified mis-
adventure during surgical and medical care), and Y88.0
(sequelae of adverse effects caused by drugs in therapeutic
use). The likelihood of an ICD-10 code representing an
adverse drug event was based on the ICD-10 code descrip-
tion and on clinical reasoning (Table 1).
Definitions
Adverse drug events were defined as “untoward and un-
intended symptoms, signs or abnormal laboratory values
arising from the appropriate or inappropriate use of
prescription or over-the counter medications” [30-32].
All cases deemed adverse drug events had to be associ-
ated with an emergency department visit. Adverse drug
events were distinguished from drug-related problems
by the presence of untoward and unintended symptoms,
signs or abnormal laboratory values. Once identified, ad-
verse drug events were classified into mutually exclusive






A1 The ICD-10 code description includes the phrase
“induced by medication/drug.”
11
A2 The ICD-10 code description includes the phrase
“induced by medication or other causes.”
81
B1 The ICD-10 code dictionary includes the phrase “poison-
ing by medication.”
13
B2 The ICD-10 code dictionary includes the phrase “poison-
ing by or harmful use of medication or other causes.”
19
C§ Adverse drug event deemed to be very likely although
the ICD-10 code description does not refer to a drug.
32
D§ Adverse drug event deemed to be likely although the
ICD-10 code description does not refer to a drug.
86
E§ Adverse drug event deemed to be possible although
the ICD-10 code dictionary does not refer to a drug.
85
*The code descriptions are from the ICD-10 coding dictionary [29].
§The likelihood of the ICD-10 code indicating an adverse drug event was adapted f
investigators who arrived at their ratings independently, and subsequently obtained[25]. Those due to drug exposure were classified as: (1)
adverse drug reactions, defined as noxious and/or unin-
tended responses to medication which occurred despite
appropriate drug dosage for prophylaxis, diagnosis or
therapy of the indicating medical condition; [32] (2) drug
interaction, (3) drug use without indication, or (4)
supratherapeutic/high dose. Adverse events related to al-
cohol abuse and illicit drugs were not considered ad-
verse drug events. Adverse drug events due to lack of
exposure to a drug were classified as: (6) subtherapeutic/
low dose, (7) need to add drug/untreated indication, (8)
wrong drug, or (9) noncompliance/failure to receive
drug [11,30,31,33] Cases in which drugs were never con-
sidered for use in the first place were not considered ad-
verse drug events. Adverse drug events were categorized
into chief-complaint-related events versus those found
incidentally. The former were deemed to result in the
patient’s presenting complaint (i.e., a non steroidal anti-
inflammatory drug leading to a gastrointestinal bleed, in
which the patient’s complained of “vomiting blood”).
The latter, were not deemed to result in the patient’s
presenting complaint (i.e., hydrochlorothiazide leading
to an abrupt and significant decline in serum sodium in
a patient presenting with a skin infection). The emer-
gency physician assigned an adverse drug event severity
category at the point-of-care: A severe event caused
death or required admission, a moderate event required
a change in medical management, and a mild event re-
quired no change in therapy [22-24]. The categorizations
of adverse drug events by chief-complaint and severity






4 J70.2 Acute drug-induced interstitial lung disorders
142.7 Cardiomyopathy due to drugs and other external agents
T88.7 Unspecified adverse event of drug or medicament
4 T36 Poisoning by systemic antibiotics
X44 Accidental poisoning by, and exposure to, other and
unspecified drugs, medicaments and biological
substances
L51.2 Toxic epidermal necrolysis
N17 Acute renal failure with tubular necrosis
K25 Gastric ulcer
Y66 Non administration of surgical and medical care
rom Stausberg et al., [27,28] and where missing, was determined by two
consensus through discussion (CH and JS).
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We used descriptive statistics to summarize the base-
line characteristics of the patient population. We esti-
mated the proportion of patients with at least one
adverse drug event code recorded in the administrative
hospital or emergency department database among
those who were diagnosed with one or more adverse
drug events at the point-of-care. This was estimated as
the number of patients with recorded adverse drug
event codes in categories A1, A2, B1 or B2 in the ad-
ministrative database, divided by the number of pa-
tients with adverse drug events diagnosed at the point-
of-care in the prospective database multiplied by 100.
We estimated the proportion of false positives by divid-
ing the number of patients with at least one adverse
drug event code recorded in the administrative data-
base and no adverse drug events identified at the point-
of-care by the number of all patients without adverse
drug events identified at the point-of-care, multiplied
by 100. As the likelihood of an ICD-10 code identifying
a true adverse drug event varied, we expanded the nu-
merator to include codes in categories C, D, or E.Results
Adverse drug events identified at the point-of-care
Among 2289 patients who were approached for enrolment,
1591 met the prospective study’s inclusion and exclusion
criteria (Figure 1) [21]. Among these, 17 were excluded be-
cause they had multiple visits on the same day in the ad-







Figure 1 Patient flow.The place of presentation was distributed unevenly be-
tween the two emergency departments: 1152 (73.2%) pa-
tients presented to VGH, and 422 (26.8%) to SPH. The
average age was 51.4 years, 51.1% were female, and the me-
dian number of prescribed medications was two (Table 2).
Among these patients, 221 (14%, 95% confidence interval
12.4–15.8%) were diagnosed with 237 adverse drug events
at the point–of–care (Table 3). One hundred and forty six
patients (146/221; 66.1% 95% CI 59.6–72.0%) had one ad-
verse drug event related to their chief–complaint, 60 (60/
221; 27.1 95% CI 21.7–33.4%) had one incidentally found
event, and 15 (15/221; 6.8% 95% CI 4.2–10.9%) had more
than one adverse drug event. The most common categories
of adverse drug events resulted from adverse drug reac-
tions (74/237; 33.5%; 95% CI 27.6–40.0%) (Table 3). Other
categories of adverse drug events were due to noncompli-
ance/failure to receive a drug (62/237; 26.2%; 95% CI 21.0-
32.1%), need to add a drug/untreated indication (35/237;
14.8%; 95% CI 10.8-19.9%), subtherapeutic/low dose (27/
237; 11.4%; 95% CI 8.0-16.1%), supratherapeutic/high dose
(20/237; 8.4%; 5.5-12.7 95% CI), wrong drug (15/237;
6.3%; 95% CI 3.9-10.2%) and drug use without indication
(4/237; 1.7%; 95% CI 0.7-4.2%). No adverse drug events
were attributed to drug interactions.
Most adverse drug events (226/237; 95.4%; 95% CI
91.9.0–97.4%) were deemed at least moderate in severity,
requiring a change in medical management, consultation,
hospital admission, or were life-threatening. The most
commonly implicated medications were acetaminophen
with codeine (15 events), warfarin (15 events) and pheny-
toin (9 events).








(n = 158) (n = 63) (n = 1,353)
Age, yrs, mean (SD) 51.4 (20.3) 50.8 (20.8) 63.5 (19.7) 50.9 (20.1)
Female 805 (51.1%) 76 (48.1%) 26 (41.3%) 703 (52.0%)
Arrived from, no. (%)†
Home 1404 (89.2%) 131 (82.9%) 56 (88.9%) 1217 (89.9%)
Homeless/Shelter 64 (4.1%) 14 (8.9%) 2 (3.2%) 48 (3.5%)
Nursing home 65 (4.1%) 9 (5.7%) 3 (4.8%) 53 (3.9%)
Other 39 (2.5%) 4 (2.5%) 2 (3.2%) 33 (2.4%)
Canadian triage acuity score, no. (%)
1 6 (0.4%) 2 (1.3%) 0 (0.0%) 4 (0.3%)
2 225 (14.3%) 20 (12.7%) 10 (15.9%) 195 (14.4%)
3 693 (44.0%) 77 (48.7%) 36 (57.1%) 580 (42.9%)
4 579 (36.8%) 50 (31.6%) 14 (22.2%) 515 (38.1%)
5 71 (4.5%) 9 (5.7%) 3 (4.8%) 59 (4.4%)
Most common chief complaints, no. (%)
Abdominal pain 157 (10.0%) 4 (2.5%) 9 (14.3%) 144 (10.6%)
Chest pain 115 (7.3%) 4 (2.5%) 4 (6.4%) 107 (7.9%)
Shortness of breath 96 (6.1%) 14 (8.9%) 5 (7.9%) 77 (5.7%)
Lower extremity pain 79 (5.0%) 4 (2.5%) 2 (3.2%) 73 (5.4%)
Back pain 64 (4.1%) 4 (2.5%) 0 (0.0%) 60 (4.4%)
No. comorbid conditions, mean (SD) 2.1 (2.0) 2.7 (2.2) 3.3 (1.8) 1.9 (2.0)
Most prevalent comorbid conditions, no. (%)
Hypertension 382 (24.3%) 43 (27.2%) 36 (57.1%) 303 (22.4%)
Mood disorder 201 (12.8%) 35 (22.2%) 7 (11.1%) 159 (11.8%)
Dyslipidemia 125 (7.9%) 15 (9.5%) 5 (7.9%) 105 (7.8%)
Asthma 120 (7.6%) 20 (12.7%) 6 (9.5%) 94 (6.9%)
Diabetes Mellitus 119 (7.6%) 22 (13.9%) 9 (14.3%) 88 (6.5%)
No. prescribed medications, median (IQR) 2 (1,5) 4 (2,7) 4 (2,8) 2 (1,5)
Most commonly prescribed outpatient medications, no. (%)
Acetaminophen with codeine 195 (12.4%) 29 (18.4%) 8 (12.7%) 158 (11.7%)
Ramipril 134 (8.5%) 12 (7.6%) 7 (11.1%) 115 (8.5%)
Salbutamol 123 (7.8%) 16 (10.1%) 8 (12.7%) 99 (7.3%)
Rabeprazole 117 (7.4%) 12 (7.6%) 10 (15.9%) 95 (7.0%)
Lorazepam 106 (6.7%) 7 (4.4%) 6 (9.5%) 93 (6.9%)
Disposition from the ED, no. (%)‡
Admitted 283 (18.0%) 40 (25.3%) 20 (31.7%) 223 (16.5%)
Home 1279 (81.3%) 113 (71.5%) 42 (66.7%) 1124 (83.1%)
Deceased 3 (0.2%) 0 (0.0%) 0 (0.0%) 3 (0.2%)
Other 7 (0.4%) 5 (3.2%) 1 (1.6%) 1 (0.1%)
Abbreviations: ADE = adverse drug event, SD = standard deviation, IQR = interquartile range,.
†There were two patients who arrived from an unknown location.
‡There were two patients with unknown disposition from the ED.
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Table 3 Characteristics of 237 adverse drug events
identified at the point-of-care in 1574 emergency depart-
ment patients





(n = 158) (n = 79)
Type
Adverse drug reaction 48 (30.4) 26 (32.9)
Drug interactions 0 (0.0) 0 (0.0)
Drug use without indication 3 (1.9) 1 (1.3)
Supratherapeutic/high dose 12 (7.6) 8 (10.1)
Subtherapeutic/low dose 13 (8.2) 14 (17.7)
Need to add drug/untreated
indication
25 (15.8) 10 (12.7)
Noncompliance/failure to
receive drug
45 (28.5) 17 (21.5)
Wrong drug 12 (7.6) 3 (3.8)
Severity
Severe 21 (13.1) 3 (3.8)
Moderate 131 (82.9) 71(89.9)
Mild 6 (3.8) 5 (6.3)
Preventability
Preventable 118 (74.7) 60 (75.9)
Non-preventable 40 (25.3) 19 (24.1)
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administrative databases with codes clearly linking the
event to a culprit medication
We found ICD-10 codes that clearly identified an ad-
verse drug event (categories A1, A2, B1 and B2) in 15
of 221 records of patients diagnosed with one or more
adverse drug events at the point–of–care (Table 4),
corresponding to a sensitivity of 6.8% (95% CI 4.0–
11.2%). This code set identified 18 of 1353 records as
false positive (1.3%; 95% CI 0.8-2.1%), corresponding to
a specificity of 98.7% (95% CI 97.9-99.2%). The positive
predictive value of the code set was 45.5% (95% CI 28.1–
63.7%), and its negative predictive value 86.6% (95% CI
84.8 – 88.3%).Table 4 Patients with records in the administrative data indic
adverse drug events identified at the point-of-care in the em
code and type of adverse drug event
ICD-10 code category* Any ADE
(n = 221)
Induced or related to a medication (%; 95% CI) 15 (6.8; 4.0–1
Induced or related to a medication,very likely,
likely or possible ADE (%; 95% CI)
62 (28.1; 22.3–
Abbreviations: ICD = international classification of disease; ADE = adverse drug event
* “Chief complaint-related” refers to patients with at least one chief complaint-relat
** “Incidentally found” refers to patients with incidentally found ADEs only.Two of 59 adverse drug reactions (3.4%; 95% CI 0.4–
11.7%) and 3 of 22 severe adverse drug events (13.6%;
95% CI 2.9–34.9%) were identified as medication-
related in the administrative data with code categories
A1, A2, B1 or B2, among patients with only one event.
Among patients admitted to hospital from the emer-
gency department, 18.2% of adverse drug events were
identified with an ICD-10 code clearly linking the event
to medication use (Table 5). We found ICD-10 codes
that clearly linked a culprit medication to an adverse
drug event in 14 of 158 (8.9%, 95% CI 5.1–14.7%) re-
cords of patients presenting with a chief complaint-
related adverse drug event.Adverse drug events identified in the administrative data
with codes indicating a very likely, likely or possible
relationship to a medication
When the ICD-10 code categories were broadened to in-
clude codes that very likely, likely or possibly indicated
an adverse drug event, we were able to identify 62 codes
for adverse drug events in the 221 records of patients di-
agnosed with one or more adverse drug events at the
point–of–care (Table 4). This corresponded to a sensi-
tivity of 28.1% (95% CI 22.3–34.6%) for the broader code
set. The positive predictive value of the code set was
27.2% (95% CI 21.5 – 33.5%), and its negative predictive
value 88.2% (95% CI 86.3 – 89.9%).
Using the broader code set we identified 23 of 59 ad-
verse drug reactions (39.0%; 95% CI 26.6–52.6%), and
seven of 22 severe adverse drug events (31.8%; 95% CI
13.9–54.9%) among patients with one event only.
Among admitted patients, 54.6% of adverse drug events
were identified with an ICD-10 code indicating a pos-
sible, likely, or very likely adverse drug event, or clearly
linking the event to medication use (Table 5). The
broader code categories identified 45 of 158 (28.5%,
21.7%–36.3%) adverse drug events related to the chief-
complaint. This code set incorrectly identified 166 of
1353 records as false positive (12.3%; 95% CI 10.6-
14.1%), corresponding to a specificity of 87.7% (95% CI
85.9-89.4%).ating an adverse drug event among patients with
ergency department, by category of diagnostic ICD-10
Chief complaint-related Incidentally found
(n = 158)* (n = 63)**
1.2) 14 (8.9; 5.1–14.7) 1 (1.6; 0.1–9.7)
34.6) 45 (28.5; 21.7 – 36.3) 17 (27.0; 16.9–39.9)
, CI = confidence interval.
ed ADE.
Table 5 Patients with records in the administrative data indicating an adverse drug event among patients with
adverse drug events identified at the point-of-care in the emergency department, by category of diagnostic code and
admission status*
ICD-10 code category Admitted Discharged
(n = 66) (n = 146)
Induced or related to a medication (%; 95% CI) 12 (18.2; 9.8–29.6) 3 (2.1; 0.4–5.9)
Induced or related to a medication, very likely, likely or possible ADE (%; 95% CI) 36 (54.6; 41.8–66.9) 26 (17.8; 12.0–25.0)
ADE = adverse drug event; CI = confidence interval.
*Nine patients did not have admission status reported in the administrative data.
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adverse drug events (categories A1–E) were olanzapine
(five events), and warfarin, phenytoin, vancomycin, gly-
buride, clopidogrel and aspirin (two events each).
Discussion
Our objective was to determine the proportion of ad-
verse drug events to outpatient medications resulting in
emergency department visits that were reported in ad-
ministrative data. We found adverse drug events to be
underreported in the administrative data of two large
Canadian university hospitals, despite using an extensive
list of ICD-10 codes. Even when a broad set of ICD-10
codes was used to include diagnoses indicating a very
likely, likely or possible relationship with a medication,
we were only able to identify 28% of adverse drug
events, and 39% of adverse drug reactions. Among pa-
tients who required hospital admission, we were able to
identify 55% of adverse drug events.
Prescribing medication is the most common medical
intervention performed by physicians. Yet, many prescrib-
ing decisions are informed by incomplete or conflicting
evidence, or by the results of randomized trials that
may not be transferrable to clinical practice [7,34,35]. In
addition, off-label use of medications and varying compli-
ance behavior of patients contribute to suboptimal treat-
ment outcomes, leading to a growing interest in developing
improved methods to capture adverse drug event data from
the real-world to generate more robust estimates about the
comparative safety and effectiveness of medications, and to
develop interventions to improve patient care [6-8,17,18].
In North America, emergency departments offer the
majority of healthcare delivered for acute and unexpected
medical conditions, including adverse drug events [9].
Therefore, emergency department administrative data
may offer unique opportunities to capture data on clinic-
ally significant adverse drug events that result from out-
patient medication use [9,11-13]. However, before such
data are considered for this purpose, they should be evalu-
ated for their completeness.
Our study is the first in the peer-reviewed literature to
compare adverse drug event reports in administrative re-
cords of emergency department patients with adversedrug events diagnosed at the point-of-care. Prior studies
have attempted to validate adverse drug event codes in
administrative data by comparing adverse drug event re-
ports in administrative data to events identified by chart
review, using electronic trigger methods or between ad-
ministrative databases [36-41]. Our study differs from
these studies in the premise that all clinically significant
adverse drug events are recorded in the medical record
or identifiable using trigger methods. Indeed, two prior
studies support the assumption that 40% of adverse drug
events may not be documented in emergency depart-
ment records [33,42]. Therefore, in order to understand
the sensitivity of administrative data and the ICD-10
code set, we derived our criterion standard at the point-
of care using a pre-defined algorithm that included as-
sessment by a pharmacist and a physician. We believe
that this led to more precise estimates of adverse drug
events. We disclosed all adverse drug events suspected
in the emergency department to treating physicians (re-
quired by Ethics to ensure optimal patient care) prior to
coding, thus optimizing the chances of their documenta-
tion in the medical chart.
A few studies have examined the sensitivity of adverse
drug event codes within the ICD-9 coding system for events
that occurred as a result of inpatient medications [38,39].
Hougland et al. found that their code set detected more
events than the hospital’s computerized adverse drug event
surveillance system, and estimated that 55% of adverse drug
events causing hospitalization, and 10% of adverse drug
events occurring during the course of hospitalization were
identified when compared to medical record review [38].
Leonard et al. found that the sensitivity of their ICD-9 code
set varied substantially by the type of adverse drug reaction
they searched for, and estimated that the sensitivity of the
codes for digoxin and phenytoin related events may be 84%
and 86.7% respectively [39]. However, the authors deter-
mined the criterion standard retrospectively by chart review
in only 19-40% of records, all of which had been were pre-
screened using an ICD-9 code set that included the adverse
drug reaction codes [39]. This may have falsely elevated the
sensitivity of their code set, because the determination of
the criterion standard was not independent of the code set
they used to identify events.
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of emergency department data coded in ICD-10 for ad-
verse drug reactions [41]. Wu et al. used CIHI data to
compare the emergency department discharge diagnosis
with the admitting diagnosis among patients who were
admitted to the hospital through emergency depart-
ments. The authors’ premise was that in patients admit-
ted to hospital through the emergency department for a
diagnosis of an adverse drug reaction, the patient’s emer-
gency department discharge diagnosis and hospital ad-
mitting diagnosis should be the same, if adverse drug
reactions are appropriately identified, recorded and
coded. Using an ICD-10 code set containing 245 codes
including the external cause codes Y40-59, Wu et al.
found that 15% of emergency department visits for adverse
drug reactions leading to hospital admission were coded
with the corresponding admitting diagnosis in CIHI. In
comparison, in our study including all emergency depart-
ment patients (not just those admitted to hospital), we
were only able to identify 3.4% of adverse drug reactions
in the administrative data using our “narrower” code set
containing ICD-10 codes categorized as A1, A2, B1 and
B2. We believe that this large difference in our estimate
of the degree of underreporting may be due to Wu et al.’s
comparison of adverse drug reactions coded within one
set of administrative data (NACRS) to another (the Dis-
charge Abstract Database), as opposed to our compari-
son with a prospective standard. This indicates that
adverse drug event reporting may be overestimated
when reporting is evaluated by comparing between two
administrative databases.
The strengths of our study include a rigorous assess-
ment of adverse drug events at the point-of-care before
any administrative coding occurred. Both a clinical
pharmacist and a treating emergency physician assessed
all patients in our cohort. The clinical pharmacists in our
study evaluated patients independently from physicians,
and took their own medical histories, contributing to the
accuracy of the available medication information rather
than relying on retrospective chart review. Pharmacists
documented any suspected adverse drug events in the pa-
tients’ records and informed physicians of all potentially
missed cases. All cases in which the pharmacists’ and phy-
sicians’ assessments of adverse drug events were discord-
ant or uncertain were reviewed and adjudicated by an
independent committee consisting of a clinical pharmacist
and a medical toxicologist. Another strength of our study
includes having conducted a literature review to identify
adverse drug event codes in the ICD-10 coding system, re-
ducing the possibility that we underestimated the capacity
of the ICD-10 coding system to identify adverse drug
events by using too narrow of a code set [26].
The operational definition of adverse drug events re-
mains problematic, as several interpretations of its mostcommon definition “harm caused by the use of a drug”
exist [30,31]. We approached our case definition of ad-
verse drug events from the health services research per-
spective, in which the utilization of the emergency
department leading to bed occupancy and incurring cost
was the primary end point. Thus, all our cases were as-
sociated with an emergency department visit, and we did
not capture any “harm” or injury” from illnesses not as-
sociated with an emergency department visit. Despite
this, not all of the events captured in our study will be
of interest from a pharmacovigilance or regulatory body
perspective. From the latter perspective, adverse drug re-
actions, a subset of adverse drug events, are most rele-
vant. Examples of events falling into our case definition
that may not be relevant from a pharmacovigilance or
regulatory body perspective were the following: the need
to add a drug/untreated indication (e.g., lack of anticoa-
gulation therapy leading to stroke in a patient with a
previously established diagnosis of atrial fibrillation, a
high CHADS2 score and previous documentation of the
need for anticoagulation), too high or too low dose (e.g.,
a reduction in furosemide dose leading to pulmonary
edema in a patient with previously controlled congestive
heart failure and no alternate explanation), noncompli-
ance/failure to receive a drug (e.g., noncompliance
with insulin leading to diabetic ketoacidosis) or wrong
drug (e.g., a patient with type II diabetes mellitus with
recurrent episodes of hypoglycemia on glyburide). We
deemed the inclusion of these types of events important
from a health services research perspective, as these
types of events have previously been associated with in-
creased health services utilization and cost, [43] and
many were classified as preventable [21]. From a patient,
clinician and system perspective, the development of
methods to identify and monitor these types of events is
desirable to generate a factual basis for generating hy-
potheses about their prevention and to inform health
policies to reduce their occurrence. These may include
specific actions related to prescribing, administering or
monitoring of high-risk medications, or actions targeting
specific patient groups. Data on the extent of occurrence
and associated burden of events can be used to prioritize
actions in a resource-constrained environment to target
commonly occurring preventable and costly events.
For example, through a recently implemented adverse
drug event screening program in the Vancouver Costal
Health Authority, through which detailed regional ad-
verse drug event data are collected, our group identified
that a large proportion of emergency department visits
can be attributed to supratherapeutic/high warfarin dose
without any associated bleeding. Identifying the etiologic
cause of these visits is informing the development of
specific preventative policies within the Health Author-
ity, as well as the discourse between primary care and
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In order to ensure that we did not apply too broad of
a case definition of adverse drug events, we put mecha-
nisms in place to ensure that events that could be ex-
plained by the exacerbation of the patient’s underlying
disease or by alternate diagnoses were excluded. These
mechanisms included capturing the physician’s working
diagnosis, mandating the use of causality algorithms
and using an independent adjudication committee. We
did not consider the failure to use drug in the first place as
an adverse drug event, unless the drug had clearly been
documented as being indicated in the patient’s medical
record. We put these safeguards in place, as adopting too
broad of a case definition and overcalling cases as adverse
drug events that might not be, may risk promoting in-
appropriate use of non-medicinal therapies, and may not
serve to promote prudent and rational medication use.
Our study is not without limitations. First, we consid-
ered all adverse drug events that had been reported in
either primary or secondary diagnostic codes, because
some patients presented to the emergency department
with more than one adverse drug event, one of which
may have been coded under a secondary diagnosis field.
Also, some patients may have been diagnosed with more
than one diagnosis in the emergency department, one of
which was deemed the primary reason for presentation
or admission. Therefore, we did not exclude adverse
drug event codes that were coded in secondary diagnosis
fields in order to avoid underestimating the sensitivity of
the administrative dataset and the ICD-10 code set.
However, this means that we may have picked up ad-
verse drug events that resulted from in-hospital treat-
ment rather than from outpatient medications. This
would have resulted in an overestimation of the sensitiv-
ity of the ICD-10 codes. Second, because of the cost and
labor involved in establishing a prospective standard for
adverse drug events, our sample size is limited. Thus,
our study should be regarded as preliminary. Third, our
results reflect two Canadian institutions and may not be
generalizable to other institutions. Fourth, we expanded
our code set to include possible adverse drug events
(code categories C, D and E), to allow for better ICD-10
data capture which resulted in a greater proportion of
false positives. Fifth, our results may have been influ-
enced by the existing variation in the use of the termin-
ology surrounding adverse drug events [31]. It is
possible that physicians were less likely to record (and
coders less likely to code) events that they personally felt
should not be considered drug-related, even though the
presentation met our outcome definition. Finally, we
wish to clarify why the number of events listed in this
study differs from its parent study [21]: The prospective
data used for this study was derived from a prospectiveobservational clinical decision rule derivation study in
which we collected data on all outcomes (n = 221). The
purpose of the parent study was to derive clinical deci-
sion rules to aid health care workers at the point-of-care
to identify patients with a broad range of adverse drug
events. Yet, this was not possible, likely due to the het-
erogeneity of the events. Therefore, as stated a priori in
the protocol of our parent study, we proceeded to derive
clinical decision rules for two narrower categorizations
of adverse drug events. Thus, the clinical decision rule
derivation study represents a subset of the events ana-
lyzed in the present study.
Conclusion
We found adverse events to outpatient medications result-
ing in emergency department visits to be underreported in
existing administrative data of two large Canadian tertiary
care hospitals. The performance characteristics of the code
sets examined, in terms of their sensitivity, specificity, posi-
tive and negative predictive values, indicate that adminis-
trative data alone may not be appropriate as a stand-alone
means of identifying adverse drug events in these data.
This study may serve as a point of reference for future
work in this area, considering the paucity of the literature
on evaluating the ICD-10 system and emergency depart-
ment administrative data for adverse drug event reports.
Future research on differential reporting of outpatient ad-
verse drug events in administrative data would be useful to
gain a better understanding of those events for which ad-
ministrative data may have a greater sensitivity [38]. Finally,
despite the cost and labor involved in establishing adverse
drug event surveillance systems using prospective data, ac-
tive case finding methods may result in more complete
and accurate estimates compared with administrative data.
Additional files
Additional file 1: ADE Evaluation Algorithm at the Point-of-Care.
In the ED each patient was evaluated by a clinical pharmacist and the
treating emergency physician independently, and blinded to each other’s
evaluations. The ratings were combined while the patient was still in the
ED. If there was any disagreement about the rating (i.e., yes/no, yes/uncertain,
no/uncertain, etc.), or if either or both of the evaluations were uncertain, the
case proceeded to independent adjudication by a committee consisting of a
pharmacist and physician not in any other way involved in the study.
Additional file 2: Adverse drug events were diagnosed only in
patients presenting to the emergency department with untoward
and unintended symptoms, signs or abnormal laboratory values
that arose from appropriate or inappropriate medication use. Events
meeting this case definition were categorized according to the taxonomy
of drug-related problems [25]. For all events that were categorized as
due to “Need to Add Drug/Untreated Indication” or “Failure to Receive a
Drug/Noncompliance” a pre-existing diagnosis had to have been docu-
mented prior to the emergency department visit. Failure to use a drug in
the first place was not considered an adverse drug event. Asymptomatic
drug-related problems were not captured. Adverse drug reactions were
defined according to the World Health Organization [31].
Additional file 3: See code set provided in an Excel spreadsheet.
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